Edwards Lifesciences (EW) earnings call transcript summary & sentiment

Our read on the 23 July 2026 earnings call

Overall tone

Positive

Executive Summary

Edwards Lifesciences delivered strong Q2 performance with total sales rising 12.5% year-over-year to $1.74 billion, led by a 10.5% increase in TAVR and a 44.8% surge in TMTT revenue.

Core Signals

Revenue Growth & Demand: Q2 total sales increased 12.5% year-over-year to $1.74 billion, driven by balanced procedural growth across global markets and multi-platform structural heart expansion.

Bullish Signals

Full-year sales growth guidance was raised across total company (10–11%), TAVR (8–9%), and TMTT ($760–$780 million) following strong Q2 operational execution.

Risk Signals

Foreign exchange headwinds reduced Q2 gross margin by 70 bps and are dragging full-year gross margin to the lower end of the 78–79% target range.

Q&A Signals

Repeated analyst topics: Analysts focused repeatedly on the PROGRESS trial baseline characteristics, the timeline for commercializing moderate aortic stenosis, and 2H seasonality drivers.

Key Investor Debate

The key investor debate centers on whether major pipeline milestones—specifically the CMS TAVR NCD update and the PROGRESS moderate aortic stenosis trial results—can meaningfully accelerate core TAVR growth beyond the mid-to-high single-digit trajectory.

Analyst Takeaway

Management demonstrated strong operational control and tone, supported by synchronized beats across regions and product categories.